DZD9008 In Combination With Bevacizumab in Locally Advanced or Metastatic NSCLC Patients With EGFR Mutation (WU-KONG29)
A phase 2 trial of Sunvozertinib and Bevacizumab in non-small-cell lung cancer, run by Dizal Pharmaceuticals, now recruiting.
Overview
DZD9008 In Combination With Bevacizumab in Locally Advanced or Metastatic NSCLC Patients With EGFR Mutation (WU-KONG29) is a phase 2 interventional study registered as NCT06276283 by Dizal Pharmaceuticals, with 60 participants planned, started 2023-02-15 and due to reach its primary completion in 2025-12-31. Interventions recorded: DZD9008 plus Bevacizumab.
Similar pages
not linked directly; found by shared links- TrialA Phase 1/2 Study of GW5282 in Participants With Advanced Solid Tumors
Shares Dizal Pharmaceutical and the tag pipeline.
- TrialAssessing an Oral EGFR Inhibitor, Sunvozertinib in Patients Who Have Advanced Non-small Cell Lung Cancer With EGFR or HER2 Mutation (WU-KONG1)
Shares Sunvozertinib, Dizal Pharmaceutical, Non-small-cell lung cancer.
- TrialSunvozertinib (DZD9008) in Pretreated Lung Cancer Patients with EGFR Exon20 Insertion Mutation (WU-KONG6)
Shares Sunvozertinib, Dizal Pharmaceutical, Non-small-cell lung cancer.
- TrialA Phase II Clinical Trial of DZD9008 in Combination With AZD4205 in Standard Treatment Failed NSCLC Patients With EGFR Mutations (WU-KONG21)
Shares Sunvozertinib, Dizal Pharmaceutical, Non-small-cell lung cancer.
- TrialDZD8586 in Patients With Relapsed or Refractory CLL/SLL (TAI-SHAN8)
Shares Dizal Pharmaceutical and the tag pipeline.
- TrialAssessing Treatment of T-Cell Lymphoma With GW5282 in Combination With Golidocitinib (BEI-DOU3)
Shares Dizal Pharmaceutical and the tag pipeline.
- TrialA Study of DZD8586 Combination in CLL/SLL (TAI-SHAN10)
Shares Dizal Pharmaceutical and the tag pipeline.
- TrialA Study of BMS-986490 With or Without Bevacizumab in Advanced Solid Tumors
Shares Bevacizumab and the tag pipeline.